Actualités 18 mar 2024 Neuria intègre l’accélérateur Vanguard pour promouvoir des modes de vie plus sains Neuria Digital Therapeutics est la première start-up de 2024 à bénéficier du programme Vanguard Accelerator.
Actualités 12 jan 2022 ObsEva obtient des résultats positifs dans le traitement de l’endométriose Spécialisée dans la santé des femmes, la société biopharmaceutique genevoise ObsEva a annoncé des résultats préliminaires positifs de l'essai de ...
Aktuell 11 out 2023 LimmaTech Biologics nimmt 37 Millionen Dollar ein LimmaTech Biologics nimmt in einer Serie A-Finanzierungsrunde 37 Millionen Dollar ein. Damit soll die weitere Entwicklung der Impfstoff-Pipeline ...
News 12 jan 2022 ObsEva achieves positive results in the treatment of endometriosis Geneva-based women’s health biopharmaceutical company ObsEva has announced positive topline results from the Phase 3 EDELWEISS 3 trial of linzago...
News 10 mai 2024 BioVersys extends Series C financing round to 44.9 million Swiss francs BioVersys is bolstering its partnership with GSK in order to accelerate the development of alpibectir for the treatment of tuberculosis. GSK is s...
News 16 ago 2023 Spexis receives capital commitment of 2.5 million US dollars Investors have made an additional capital commitment to Spexis AG. With an extra 2.5 million US dollars at its disposal, the biopharmaceutical fi...
Actualités 14 fev 2024 L’Université de Fribourg découvre un traitement pour combattre la neuroinflammation liée à l’âge Des scientifiques de l’Université de Fribourg ont découvert un mécanisme révolutionnaire qui pourrait atténuer de manière significative la neuroi...
News 07 mai 2024 UZH researching innovative cancer therapy Researchers from the University of Zurich (UZH) are in the process of developing new cancer therapeutics. Known as radiotheranostics, these drugs...
News 08 ago 2023 Do Tank Aargau aims to strengthen life sciences sector The pilot project Do Tank Aargau is being launched by the canton of Aargau, the city of Baden and Baden Cantonal Hospital (KSB) with the aim of s...
Aktuell 22 jan 2024 DISCO Pharmaceuticals startet mit 20 Millionen Euro Kapital DISCO Pharmaceuticals ist mit einem Startkapital von 20 Millionen Euro neu auf dem Markt. Sein Team hat als erstes eine Methode entwickelt, die e...
News 29 jan 2024 Biomanufacturing innovator Stämm opens its European R&D facility in Monthey Stämm, an innovative leader in bioprocessing technology, has announced the opening of its new R&D facility at the BioArk in Monthey, in the canto...
Aktuell 16 ago 2023 Spexis erhält Kapitalzusage in Höhe von 2,5 Millionen Dollar Investoren lassen der Spexis AG weitere Investitionen zukommen. Mit zusätzlichen 2,5 Millionen Dollar will das biopharmazeutische Unternehmen die...
News 22 jan 2024 DISCO Pharmaceuticals secures seed funding of 20 million euros DISCO Pharmaceuticals has secured seed funding of 20 million euros and officially launched the business. The team was the first to develop a meth...
Aktuell 08 ago 2023 Do Tank Aargau soll Life Sciences-Branche stärken Mit dem Pilotprojekt Do Tank Aargau stärken der Kanton Aargau, die Stadt Baden und das Kantonsspital Baden (KSB) die Life Sciences-Branche im Kan...
Success stories 02 mai 2024 BeiGene promuove l’accesso globale ai trattamenti antitumorali: ecco come Dalla sede europea di Basilea, in Svizzera, BeiGene collabora strategicamente con stakeholder in tutto il mondo per far progredire la ricerc...
News 30 abr 2024 Top Stories from Western Switzerland (April 2024) From biotech breakthroughs and the transformation of clinical trials to advancements in eco-friendly materials and renewable energy initiatives, ...
News 02 jun 2023 Sandoz decides on Basel for headquarters Sandoz AG will continue to have its headquarters in Basel as an independent company. The separation from Novartis is expected to take place in th...